Efficiency of the Inclusion of Rebamipide in the Eradication Therapy for Infection: Meta-Analysis of Randomized Controlled Studies.

BACKGROUND

There has been a negative trend in the effectiveness of classic eradication therapy regimens for (), which has largely been determined from the emergence and spread of antibiotic resistance. Several studies have shown that adding rebamipide to eradication regimens leads to an increase in the effectiveness of treatment.

AIM

To evaluate the efficacy and safety of including rebamipide in the eradication regimens for infection.

METHODS

The literature search was conducted in the MEDLINE/PubMed, EMBASE, Cochrane Central Register, Korean Medical Citation Index, and Russian Science Citation Index databases. All identified randomized controlled trials comparing rebamipide supplementation with non-rebamipide-containing eradication regimens for the treatment of infection were included in the final analysis.

RESULTS

We identified 11 randomized controlled trials (RCTs) involving 1227 patients (631 in groups with rebamipide and 596 in groups without rebamipide). The meta-analysis showed that the addition of rebamipide to eradication regimens significantly increased the effectiveness of treatment (odds ratio (OR) 1.753, 95% confidence interval (CI) 1.312-2.333, < 0.001). The subgroup analysis demonstrated that rebamipide significantly increased the effectiveness of eradication when added to a dual therapy regimen (OR 1.766, 95% CI: 1.167-2.495, = 0.006); however, no significant improvement in effectiveness was observed when it was added to the triple therapy regimen (OR 1.638, 95% CI 0.833-3.219, = 0.152).

CONCLUSION

This meta-analysis demonstrated that the addition of rebamipide to eradication regimens significantly increases the effectiveness of treatment.